1-3 of 3
Peter Marks, MD
Close
Sort by
Journal Articles

Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study.

Mark Kirschbaum, MD, Ivana Gojo, MD, Stuart L. Goldberg, MD, Lisa Kujawski, Ehab Atallah, Peter Marks, MD, PhD, Donna Di Gravio, Lisa Pyle, Syed Rizvi, Jean-Pierre J Issa, MD
Journal: Blood
Blood (2009) 114 (22): 2089.
https://doi.org/10.1182/blood.V114.22.2089.2089
Published: 2009
Journal Articles

Left Ventricular Cardiac Function during the Course of a One Year Multicenter Trial of the Safety and Efficacy with ICL670 5–40mg/kg/day and Deferoxamine 20–60 mg/kg/day in Beta-Thalassemia Patients with Transfusional Hemosideosis.

Dorothy A. Kleinert, NP, MPH, Erica Jones, MD, Cristina P. Sison, PhD, Peter Marks, MD, PhD, Patricia J. Giardina, MD
Journal: Blood
Blood (2005) 106 (11): 3853.
https://doi.org/10.1182/blood.V106.11.3853.3853
Published: 2005
Journal Articles

Control of Oxidant-Stress and Inflammation by Iron Chelators Deferasirox (ICL670) or Deferoxamine in β-Thalassemia: An Ancillary Study of the Novartis CICL670A0107 Trial.

Patrick Walter, PhD, Eric Macklin, PhD, John Porter, MD, Patricia Evans, PhD, Tom Coates, MD, Nancy F. Olivieri, MD, Patricia Giardina, MD, Janet Kwiatkowski, MD, Ellis Neufeld, MD, Bruce Ames, PhD, Jaymes Holland, Peter Marks, MD, Elliott Vichinsky, MD, Paul Harmatz, MD
Journal: Blood
Blood (2005) 106 (11): 3598.
https://doi.org/10.1182/blood.V106.11.3598.3598
Published: 2005